These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

459 related articles for article (PubMed ID: 20410258)

  • 1. IL-6: from its discovery to clinical applications.
    Kishimoto T
    Int Immunol; 2010 May; 22(5):347-52. PubMed ID: 20410258
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interleukin-6: discovery of a pleiotropic cytokine.
    Kishimoto T
    Arthritis Res Ther; 2006; 8 Suppl 2(Suppl 2):S2. PubMed ID: 16899106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IL-6: from laboratory to bedside.
    Kishimoto T
    Clin Rev Allergy Immunol; 2005 Jun; 28(3):177-86. PubMed ID: 16129902
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interleukin 6: from bench to bedside.
    Nishimoto N; Kishimoto T
    Nat Clin Pract Rheumatol; 2006 Nov; 2(11):619-26. PubMed ID: 17075601
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stimulation of EBV-activated human B cells by monocytes and monocyte products. Role of IFN-beta 2/B cell stimulatory factor 2/IL-6.
    Tosato G; Gerrard TL; Goldman NG; Pike SE
    J Immunol; 1988 Jun; 140(12):4329-36. PubMed ID: 2836512
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interleukin 6 and its receptor in the immune response and hematopoiesis.
    Hirano T; Taga T; Matsuda T; Hibi M; Suematsu S; Tang B; Murakami M; Kishimoto T
    Int J Cell Cloning; 1990 Jan; 8 Suppl 1():155-66; discussion 166-7. PubMed ID: 2324554
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interleukin-6: from basic science to medicine--40 years in immunology.
    Kishimoto T
    Annu Rev Immunol; 2005; 23():1-21. PubMed ID: 15771564
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IFN-beta 2, B cell differentiation factor 2, or hybridoma growth factor (IL-6) is expressed and released by human epidermal cells and epidermoid carcinoma cell lines.
    Kirnbauer R; Köck A; Schwarz T; Urbanski A; Krutmann J; Borth W; Damm D; Shipley G; Ansel JC; Luger TA
    J Immunol; 1989 Mar; 142(6):1922-8. PubMed ID: 2784142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis.
    Nakahara H; Song J; Sugimoto M; Hagihara K; Kishimoto T; Yoshizaki K; Nishimoto N
    Arthritis Rheum; 2003 Jun; 48(6):1521-9. PubMed ID: 12794819
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of a two-chain IL-6 receptor system in immune and hematopoietic cell regulation.
    Taga T; Kishimoto T
    Crit Rev Immunol; 1992; 11(5):265-80. PubMed ID: 1642780
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The weight of interleukin-6 in B cell-related autoimmune disorders.
    Youinou P; Jamin C
    J Autoimmun; 2009; 32(3-4):206-10. PubMed ID: 19307104
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Physician Education: The Erythropoietin Receptor and Signal Transduction.
    Yoshimura A; Arai K
    Oncologist; 1996; 1(5):337-339. PubMed ID: 10388012
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Advances in interleukin-6 therapy].
    Ogata A; Nishimoto N; Yoshizaki K
    Rinsho Byori; 1999 Apr; 47(4):321-6. PubMed ID: 10340005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IL-2Ralpha-Directed monoclonal antibodies provide effective therapy in a murine model of adult T-cell leukemia by a mechanism other than blockade of IL-2/IL-2Ralpha interaction.
    Phillips KE; Herring B; Wilson LA; Rickford MS; Zhang M; Goldman CK; Tso JY; Waldmann TA
    Cancer Res; 2000 Dec; 60(24):6977-84. PubMed ID: 11156399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Interleukin-4: from B-lymphocyte to fibroblast].
    Salmon-Ehr V; Gillery P; Kalis B; Banchereau J; Maquart FX
    Pathol Biol (Paris); 1994 Mar; 42(3):262-8. PubMed ID: 8090577
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathogenic role of interleukin-6 in the development of sepsis. Part II: Significance of anti-interleukin-6 and anti-soluble interleukin-6 receptor-alpha antibodies in a standardized murine contact burn model.
    Pallua N; Low JF; von Heimburg D
    Crit Care Med; 2003 May; 31(5):1495-501. PubMed ID: 12771624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of lymphokines mediating B cell growth and differentiation from monoclonal anti-CD3 antibody-stimulated T cells.
    Sherris D; Stohl W; Mayer L
    J Immunol; 1989 Apr; 142(7):2343-51. PubMed ID: 2538506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The paradigm of IL-6: from basic science to medicine.
    Naka T; Nishimoto N; Kishimoto T
    Arthritis Res; 2002; 4 Suppl 3(Suppl 3):S233-42. PubMed ID: 12110143
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of IL-6 for the treatment of inflammatory diseases.
    Nishimoto N; Kishimoto T
    Curr Opin Pharmacol; 2004 Aug; 4(4):386-91. PubMed ID: 15251133
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Crucial role of the interleukin-6/interleukin-17 cytokine axis in the induction of arthritis by glucose-6-phosphate isomerase.
    Iwanami K; Matsumoto I; Tanaka-Watanabe Y; Inoue A; Mihara M; Ohsugi Y; Mamura M; Goto D; Ito S; Tsutsumi A; Kishimoto T; Sumida T
    Arthritis Rheum; 2008 Mar; 58(3):754-63. PubMed ID: 18311788
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.